在ccRCC中,SETD2的抑制促进了埃拉斯诱导的铁亡
Wei Xue1, Wengang Jian1, Yuyang Meng1
1Department of Urology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Cell death & disease
|August 21, 2023
概括
低水平的SETD2表观遗传分子与清细胞细胞癌 (ccRCC) 的不良预后相关. 抑制SETD2可增强铁灭症的敏感性,这表明SETD2是ccRCC的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 清细胞细胞癌 (ccRCC) 是最常见的癌亚型,预后不佳.
- 含有SET域2 (SETD2) 的基因组甲基转移酶在ccRCC中经常表达不充分并发生突变.
- 在癌中观察到一种独特的细胞死亡途径 - - 铁亡,但其与SETD2的联系尚不清楚.
研究的目的:
- 调查ccRCC中SETD2表达和铁亡之间的关系.
- 阐明连接SETD2,基因素修饰和铁灭的基础分子机制.
- 在ccRCC中评估SETD2作为潜在的治疗点.
主要方法:
- 在ccRCC组织中评估了SETD2表达水平,与预后相关.
- 在瘤细胞中进行SETD2淘汰实验.
- 测量了脂质过氧化和Fe2+水平.
- 研究了SETD2催化H3K36me3与铁甲酸酶 (FECH) 促进体之间的相互作用.
- 分析了与铁亡相关的信号通路.
主要成果:
- 在ccRCC中,SETD2表达低,并与预后不佳有关.
- 通过SETD2倒置,瘤细胞脂质过氧化和Fe2+水平增加.
- 降低的SETD2增强了对ferroptosis诱导剂埃拉斯的敏感性.
- 通过SETD2介导的H3K36三甲基化调节FECH转录和铁亡途径.
结论:
- 降低SETD2的调节促进了ccRCC中的ferroptosis敏感性.
- 向SETD2可能会提高ccRCC治疗中铁致死诱导剂的疗效.
- SETD2代表了改善ccRCC结果的潜在治疗目标.
相关概念视频
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
The Unfolded Protein Response
4.7K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
4.7K


